<DOC>
	<DOCNO>NCT00505258</DOCNO>
	<brief_summary>The purpose study assess safety efficacy ceftobiprole versus comparator hospitalize patient bacteremia .</brief_summary>
	<brief_title>Ceftobiprole Treatment Hospitalized Patients With Staphylococcus Aureus Bacteremia</brief_title>
	<detailed_description>Ceftobiprole medocaril cephalosporin antibiotic anti-MRSA ( Methicillin-Resistant Staphylococcus aureus ) activity . Ceftobiprole medocaril approve treatment bacterial blood stream infection . S. aureus major human pathogen . It cause wide range serious infection , include skin skin structure infection , infection vascular device catheter , infection heart lung , bone joint , deep tissue . Particularly challenge difficult treat blood-borne infection ( bacteremia ) . Bacteremic infection prone relapse often complicate metastatic seeding site throughout body . MRSA strain increase prevalence , incidence , virulence . Moreover , frequency patient present persistent MRSA bacteremia appear rise . The objective open label trial compare effectiveness safety ceftobiprole versus comparator patient MRSA MSSA ( methicillin-susceptible Staphylococcus aureus ) bacteremic patient . Patients meet inclusion exclusion criterion consent participate study randomly assign either ceftobiprole comparator . The primary end point time bloodstream clearance MRSA MSSA patient . Patients randomize either ceftobiprole comparator 7 day .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Hospitalized patient sign symptom suggestive systemic staphylococcal infection define protocol Female patient must postmenopausal ( least 1 year ) , surgically sterile practice effective method birth control , male partner sterilization , discretion investigator , abstinence , entry throughout study negative urine pregnancy test ( confirm negative serum pregnancy test ) screening . Female patient pregnant lactate Known suspect hypersensitivity betalactam antibiotic study medication Receipt vancomycin antistaphylococcal drug &gt; 2 calendar day prior initiation study drug Diagnosis catheterrelated GPCcl bacteremia time study enrollment Clinical finding leftsided endocarditis prior enrollment time study participation Requirement surgery seven day study therapy administration exception surgery require manage complication S. aureus bacteremia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Bacteremia</keyword>
	<keyword>Bloodstream infection</keyword>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Staphylococcal Infections</keyword>
	<keyword>MRSA</keyword>
	<keyword>MSSA</keyword>
</DOC>